Within the pharmaceutical industry, the biospecimen supply chain directly supports exploratory research and medical discovery. However, biospecimen management is complicated and many companies struggle to control pre-analytical variability, adapt to new research timeframes, and optimize their data management.
Dr. Clive Green, Director and Head of Sample Management AstraZeneca shared with Fisher BioServices a number of challenges he is facing, including AstraZeneca's transition from their research and development center in northwestern England, to a new research center to be built in Cambridge. The greater challenge going forward is, from Dr. Green's perspective, maximizing value from the biospecimens in the collection. This involves, among other issues, closing the gap in inventory management methods between the small molecule world and the world of biospecimens.
|
 |
